Condition (MeSH)
Spinal Dysraphism
ClinicalTrials.gov lists 144 trials for Spinal Dysraphism or a narrower condition beneath it. National Institutes of Health Clinical Center (CC) has the most among industry and government lead sponsors, with 3.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
139 of the 144 trials are tagged with Spinal Dysraphism itself; the rest are tagged with a narrower condition beneath it.
When did Spinal Dysraphism trials start? (24)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 2/3
- Phase 4
- Not applicable
- Observational
Top of scale: 17
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 11 |
| 2025 | 10 |
| 2024 | 9 |
| 2023 | 14 |
| 2022 | 17 |
| 2021 | 4 |
| 2020 | 8 |
| 2019 | 7 |
| 2018 | 7 |
| 2017 | 10 |
Showing 10 of 24 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 13 trials starting in 2026 and about 11 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 35 months from start to primary completion across 18 trials still running at the 2026-10-09 snapshot; registered median of 24 months across 85 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Spinal Dysraphism trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 6 |
| Phase 2/3 | 1 |
| Phase 3 | 2 |
| Phase 4 | 1 |
| Not applicable | 82 |
| Observational | 48 |
How many Spinal Dysraphism trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 6 |
| Recruiting | 26 |
| Active, not recruiting | 11 |
| Completed | 71 |
| Terminated | 6 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Spinal Dysraphism trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Institutes of Health Clinical Center (CC) | 3 |
Which drugs are being tested for Spinal Dysraphism? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Lactobacillus Rhamnosus GG | 2 |
| Bifidobacterium lactis (BB-12) | 1 |
| Folic (or folinic) acid | 1 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Autologous bone marrow mononuclear cell transplantation | 1 |
| Conventional Treatment | 1 |
| Behavioral Treatment | 1 |
| Collection of a urine sample | 1 |
| Acetazolamide Pill | 1 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Spinal Dysraphism trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| ETV or PV shunt placed | 20 | 1 |
| Preterm premature rupture of membranes (PPROM) | 19 | 1 |
| Spontaneous preterm labor | 15 | 1 |
| Urinary tract infection | 10 | 2 |
| Other Renal Related | 8 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Spinal Dysraphism? (125)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Intravesical oxybutynin for bladder capacity in children with spina bifida: the 'Place de l'OXybutynine Intravésicale chez le Patient Enfant Neurologique' (POXIPEN) trial protocol. | BJU international | 2026 | Yes |
| First-In-Human Application of Human Umbilical Cord-Derived Extracellular Vesicles in Tethered Spinal Cord Release Surgery. | Journal of extracellular vesicles | 2025 | Yes |
| Spina Bifida. | Physical medicine and rehabilitation clinics of North America | 2025 | Yes |
| Improving motor function in fetal surgery for open spina bifida. | BJOG : an international journal of obstetrics and gynaecology | 2024 | Yes |
| Fetal cardiovascular changes during open and fetoscopic in-utero spina bifida closure. | Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology | 2024 | Yes |
Showing 5 of 125 publications.
Prevalence (44)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Spina bifida and other spinal dysraphisms | Prevalence at birth | 1-5 / 10 000 | United Kingdom | GB | Exact |
| Spina bifida and other spinal dysraphisms | Prevalence at birth | 1-5 / 10 000 | United Kingdom | GB | Exact |
| Spina bifida and other spinal dysraphisms | Prevalence at birth | 1-5 / 10 000 | United States | US | Exact |
| Spina bifida and other spinal dysraphisms | Prevalence at birth | 1-5 / 10 000 | United States | US | Exact |
| Spina bifida and other spinal dysraphisms | Prevalence at birth | 1-5 / 10 000 | Italy | Not stated | Exact |
Showing 5 of 44 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Spina bifida and other spinal dysraphisms | 823 | Exact | Orphadata Science knowledge files, Product 1 |
| Spina bifida and other spinal dysraphisms | 823 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Sub-conditions in MeSH (2)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.